Abstract
ObjectivesPeripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have